CB2 receptor-selective agonists as candidates for targeting infection, inflammation, and immunity in SARS-CoV-2...

Area of Science:

• Immunology
• Pharmacology
• Virology

Background:

• COVID-19, caused by SARS-CoV-2, presents a global health challenge due to a lack of effective drugs and vaccines.
• The severe illness is characterized by hyperimmune-inflammatory responses, necessitating therapeutic strategies that reduce infectivity and modulate immunity.
• The endocannabinoid system, specifically cannabinoid type-2 receptors (CB2R), is a key target for suppressing these detrimental inflammatory responses.

Purpose of the Study:

• To explore the potential of CB2R agonists as a therapeutic strategy against COVID-19.
• To investigate the anti-inflammatory, antiviral, and immunomodulatory properties of CB2R selective ligands.
• To evaluate the feasibility of repurposing drugs targeting the CB2R for COVID-19 treatment.

Main Methods:

• Review of existing literature on CB2R ligands and their effects on inflammatory and viral pathways.
• Analysis of the mechanisms by which CB2R activation influences immune mediators like cytokines and chemokines.
• Exploration of potential off-target effects and synergistic interactions with existing drugs.

Main Results:

• CB2R selective ligands demonstrate potent anti-inflammatory, antiviral, and immunomodulatory effects.
• Activation of CB2R regulates key signaling pathways involved in immune responses, including cytokines and chemokines.
• Some CB2R ligands exhibit beneficial off-target effects, suggesting potential for adjuvant therapy.

Conclusions:

• CB2R agonists possess significant immunomodulatory, anti-inflammatory, and antiviral properties relevant to combating COVID-19.
• Selective CB2R ligands represent promising candidates for further investigation due to their therapeutic potential, safety profile, and druggability.
• Targeting CB2R may offer a novel approach to managing SARS-CoV-2 infection and its associated complications.